Challenges in the Delivery of Therapies to Melanoma Brain Metastases

Gautham Gampa, Shruthi Vaidhyanathan, Brynna Wilken-Resman, Karen E. Parrish, Svetomir Nenad Markovic, Jann N Sarkaria, William F. Elmquist

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Brain metastases are a major cause of morbidity and mortality in patients with advanced melanoma. Recent approval of several molecularly targeted agents and biologics has brought hope to patients with this previously untreatable disease. However, patients with symptomatic melanoma brain metastases have often been excluded from pivotal clinical trials. This may be in part attributed to the fact that several of the approved small-molecule molecularly targeted agents are substrates for active efflux at the blood–brain barrier, limiting their effective delivery to brain metastases. We believe that successful treatment of melanoma brain metastases will depend on the ability of these agents to traverse the blood–brain barrier and reach micrometastases that are often not clinically detectable. Moreover, overcoming the emergence of a unique pattern of resistance, possibly through adequate delivery of combination targeted therapies in brain metastases, will be important in achieving a durable response. These concepts, and the current challenges in the delivery of new treatments to melanoma brain metastases, are discussed in this review.

Original languageEnglish (US)
Pages (from-to)309-325
Number of pages17
JournalCurrent Pharmacology Reports
Volume2
Issue number6
DOIs
StatePublished - Dec 1 2016

Fingerprint

Melanoma
Brain
Neoplasm Metastasis
Therapeutics
Neoplasm Micrometastasis
Biological Factors
Clinical Trials
Morbidity
Molecules
Mortality
Substrates

Keywords

  • Active efflux
  • Blood–brain barrier
  • Drug delivery
  • Drug resistance
  • Melanoma brain metastases
  • Molecularly targeted agents

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Biochemistry
  • Genetics

Cite this

Challenges in the Delivery of Therapies to Melanoma Brain Metastases. / Gampa, Gautham; Vaidhyanathan, Shruthi; Wilken-Resman, Brynna; Parrish, Karen E.; Markovic, Svetomir Nenad; Sarkaria, Jann N; Elmquist, William F.

In: Current Pharmacology Reports, Vol. 2, No. 6, 01.12.2016, p. 309-325.

Research output: Contribution to journalReview article

Gampa, G, Vaidhyanathan, S, Wilken-Resman, B, Parrish, KE, Markovic, SN, Sarkaria, JN & Elmquist, WF 2016, 'Challenges in the Delivery of Therapies to Melanoma Brain Metastases', Current Pharmacology Reports, vol. 2, no. 6, pp. 309-325. https://doi.org/10.1007/s40495-016-0072-z
Gampa, Gautham ; Vaidhyanathan, Shruthi ; Wilken-Resman, Brynna ; Parrish, Karen E. ; Markovic, Svetomir Nenad ; Sarkaria, Jann N ; Elmquist, William F. / Challenges in the Delivery of Therapies to Melanoma Brain Metastases. In: Current Pharmacology Reports. 2016 ; Vol. 2, No. 6. pp. 309-325.
@article{930ba4dd846a4abfac51efcf961af89d,
title = "Challenges in the Delivery of Therapies to Melanoma Brain Metastases",
abstract = "Brain metastases are a major cause of morbidity and mortality in patients with advanced melanoma. Recent approval of several molecularly targeted agents and biologics has brought hope to patients with this previously untreatable disease. However, patients with symptomatic melanoma brain metastases have often been excluded from pivotal clinical trials. This may be in part attributed to the fact that several of the approved small-molecule molecularly targeted agents are substrates for active efflux at the blood–brain barrier, limiting their effective delivery to brain metastases. We believe that successful treatment of melanoma brain metastases will depend on the ability of these agents to traverse the blood–brain barrier and reach micrometastases that are often not clinically detectable. Moreover, overcoming the emergence of a unique pattern of resistance, possibly through adequate delivery of combination targeted therapies in brain metastases, will be important in achieving a durable response. These concepts, and the current challenges in the delivery of new treatments to melanoma brain metastases, are discussed in this review.",
keywords = "Active efflux, Blood–brain barrier, Drug delivery, Drug resistance, Melanoma brain metastases, Molecularly targeted agents",
author = "Gautham Gampa and Shruthi Vaidhyanathan and Brynna Wilken-Resman and Parrish, {Karen E.} and Markovic, {Svetomir Nenad} and Sarkaria, {Jann N} and Elmquist, {William F.}",
year = "2016",
month = "12",
day = "1",
doi = "10.1007/s40495-016-0072-z",
language = "English (US)",
volume = "2",
pages = "309--325",
journal = "Current Pharmacology Reports",
issn = "2198-641X",
publisher = "Springer International Publishing AG",
number = "6",

}

TY - JOUR

T1 - Challenges in the Delivery of Therapies to Melanoma Brain Metastases

AU - Gampa, Gautham

AU - Vaidhyanathan, Shruthi

AU - Wilken-Resman, Brynna

AU - Parrish, Karen E.

AU - Markovic, Svetomir Nenad

AU - Sarkaria, Jann N

AU - Elmquist, William F.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Brain metastases are a major cause of morbidity and mortality in patients with advanced melanoma. Recent approval of several molecularly targeted agents and biologics has brought hope to patients with this previously untreatable disease. However, patients with symptomatic melanoma brain metastases have often been excluded from pivotal clinical trials. This may be in part attributed to the fact that several of the approved small-molecule molecularly targeted agents are substrates for active efflux at the blood–brain barrier, limiting their effective delivery to brain metastases. We believe that successful treatment of melanoma brain metastases will depend on the ability of these agents to traverse the blood–brain barrier and reach micrometastases that are often not clinically detectable. Moreover, overcoming the emergence of a unique pattern of resistance, possibly through adequate delivery of combination targeted therapies in brain metastases, will be important in achieving a durable response. These concepts, and the current challenges in the delivery of new treatments to melanoma brain metastases, are discussed in this review.

AB - Brain metastases are a major cause of morbidity and mortality in patients with advanced melanoma. Recent approval of several molecularly targeted agents and biologics has brought hope to patients with this previously untreatable disease. However, patients with symptomatic melanoma brain metastases have often been excluded from pivotal clinical trials. This may be in part attributed to the fact that several of the approved small-molecule molecularly targeted agents are substrates for active efflux at the blood–brain barrier, limiting their effective delivery to brain metastases. We believe that successful treatment of melanoma brain metastases will depend on the ability of these agents to traverse the blood–brain barrier and reach micrometastases that are often not clinically detectable. Moreover, overcoming the emergence of a unique pattern of resistance, possibly through adequate delivery of combination targeted therapies in brain metastases, will be important in achieving a durable response. These concepts, and the current challenges in the delivery of new treatments to melanoma brain metastases, are discussed in this review.

KW - Active efflux

KW - Blood–brain barrier

KW - Drug delivery

KW - Drug resistance

KW - Melanoma brain metastases

KW - Molecularly targeted agents

UR - http://www.scopus.com/inward/record.url?scp=85017601286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017601286&partnerID=8YFLogxK

U2 - 10.1007/s40495-016-0072-z

DO - 10.1007/s40495-016-0072-z

M3 - Review article

AN - SCOPUS:85017601286

VL - 2

SP - 309

EP - 325

JO - Current Pharmacology Reports

JF - Current Pharmacology Reports

SN - 2198-641X

IS - 6

ER -